Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Sep-Oct;99(5):432-442.
doi: 10.1016/j.jped.2023.03.002. Epub 2023 Apr 21.

Performance of fecal S100A12 as a novel non-invasive diagnostic biomarker for pediatric inflammatory bowel disease: a systematic review and meta-analysis

Bendix Samarta Witarto  1 , Visuddho Visuddho  1 , Andro Pramana Witarto  1 , Mahendra Tri Arif Sampurna  2 , Abyan Irzaldy  3
Affiliations
Meta-Analysis

Performance of fecal S100A12 as a novel non-invasive diagnostic biomarker for pediatric inflammatory bowel disease: a systematic review and meta-analysis

Bendix Samarta Witarto et al. J Pediatr (Rio J). 2023 Sep-Oct.

Abstract

Objective: The incidence and prevalence of inflammatory bowel disease (IBD) in pediatric patients are increasing. Currently, the diagnostic method for IBD is inconvenient, expensive, and difficult. S100A12, a type of calcium-binding protein, detected in the feces of patients with IBD has recently been suggested as a promising diagnostic tool. Hence, the authors aimed to evaluate the accuracy of fecal S100A12 in diagnosing IBD in pediatric patients by performing a meta-analysis.

Methods: The authors performed a systematic literature search in five electronic databases for eligible studies up to July 15, 2021. Pooled diagnostic accuracies of fecal S100A12 were analyzed as the primary outcomes. Secondary outcomes were standardized mean difference (SMD) of fecal S100A12 levels between IBD and non-IBD groups and a comparison of diagnostic accuracies between fecal S100A12 and fecal calprotectin.

Results: Seven studies comprising 712 children and adolescents (474 non-IBD controls and 238 IBD cases) were included. Fecal S100A12 levels were higher in the IBD group than in the non-IBD group (SMD = 1.88; 95% confidence interval [CI] = 1.19-2.58; p < 0.0001). Fecal S100A12 could diagnose IBD in pediatric patients with a pooled sensitivity of 95% (95% CI = 88%-98%), specificity of 97% (95% CI = 95%-98%), and area under the receiver operating summary characteristics (AUSROC) curve of 0.99 (95% CI = 0.97-0.99). Fecal S100A12 specificity and AUSROC curve values were higher than those of fecal calprotectin (p < 0.05).

Conclusion: Fecal S100A12 may serve as an accurate and non-invasive tool for diagnosing pediatric IBD.

Keywords: Diagnosis; Feces; Inflammatory bowel diseases; Pediatrics; S100A12; Sensitivity and specificity.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram of the study selection process.
Figure 2
Figure 2
Quality assessment results of the included diagnostic accuracy studies according to QUADAS-2 tool.
Figure 3
Figure 3
Meta-analysis of the comparison between fecal S100A12 levels in pediatric patients with IBD and non-IBD cases. (A) Forest plot. (B) Funnel plot.
Figure 4
Figure 4
Meta-analysis of the diagnostic accuracy of fecal S100A12 for identifying pediatric IBD. (A) Sensitivity. (B) Specificity. (C) PLR. (D) NLR. (E) Diagnostic score. (F) DOR. (G) AUSROC curve. (H) Deeks’ funnel plot.
Figure 5
Figure 5
Subgroup and meta-regression analyses for the diagnostic accuracy meta-analysis of fecal S100A12 for identifying pediatric IBD.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Molodecky N.A., Soon I.S., Rabi D.M., Ghali W.A., Ferris M., Chernoff G., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54. e42. - PubMed
    1. Ye Y., Manne S., Treem W.R., Bennett D. Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007-2016. Inflamm Bowel Dis. 2020;26:619–625. - PubMed
    1. Sýkora J., Pomahačová R., Kreslová M., Cvalínová D., Štych P., Schwarz J. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol. 2018;24:2741–2763. - PMC - PubMed
    1. Däbritz J., Gerner P., Enninger A., Claßen M., Radke M. Inflammatory bowel disease in childhood and adolescence - diagnosis and treatment. Dtsch Arztebl Int. 2017;114:331–338. - PMC - PubMed
    1. Moran C.J. Very early onset inflammatory bowel disease. Semin Pediatr Surg. 2017;26:356–359. - PubMed